Switch to:
Also traded in: Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.17
ABBV's Cash-to-Debt is ranked lower than
89% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. ABBV: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
ABBV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.59 Max: No Debt
Current: 0.17
Equity-to-Asset 0.08
ABBV's Equity-to-Asset is ranked lower than
97% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. ABBV: 0.08 )
Ranked among companies with meaningful Equity-to-Asset only.
ABBV' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.11 Max: 0.69
Current: 0.08
-0.01
0.69
Interest Coverage 8.62
ABBV's Interest Coverage is ranked lower than
75% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. ABBV: 8.62 )
Ranked among companies with meaningful Interest Coverage only.
ABBV' s Interest Coverage Range Over the Past 10 Years
Min: 7.95  Med: 37.44 Max: No Debt
Current: 8.62
Piotroski F-Score: 6
Altman Z-Score: 2.14
Beneish M-Score: -2.42
WACC vs ROIC
8.84%
21.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 36.33
ABBV's Operating Margin % is ranked higher than
95% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. ABBV: 36.33 )
Ranked among companies with meaningful Operating Margin % only.
ABBV' s Operating Margin % Range Over the Past 10 Years
Min: 17.09  Med: 30.91 Max: 36.6
Current: 36.33
17.09
36.6
Net Margin % 24.07
ABBV's Net Margin % is ranked higher than
90% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. ABBV: 24.07 )
Ranked among companies with meaningful Net Margin % only.
ABBV' s Net Margin % Range Over the Past 10 Years
Min: 8.89  Med: 22.86 Max: 32.62
Current: 24.07
8.89
32.62
ROE % 119.29
ABBV's ROE % is ranked higher than
99% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. ABBV: 119.29 )
Ranked among companies with meaningful ROE % only.
ABBV' s ROE % Range Over the Past 10 Years
Min: 24.85  Med: 91.09 Max: 199.32
Current: 119.29
24.85
199.32
ROA % 9.88
ABBV's ROA % is ranked higher than
77% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. ABBV: 9.88 )
Ranked among companies with meaningful ROA % only.
ABBV' s ROA % Range Over the Past 10 Years
Min: 6.26  Med: 14.69 Max: 39.54
Current: 9.88
6.26
39.54
ROC (Joel Greenblatt) % 323.60
ABBV's ROC (Joel Greenblatt) % is ranked higher than
98% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. ABBV: 323.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABBV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 75.1  Med: 146.37 Max: 323.6
Current: 323.6
75.1
323.6
3-Year Revenue Growth Rate 10.30
ABBV's 3-Year Revenue Growth Rate is ranked higher than
63% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. ABBV: 10.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABBV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.7 Max: 10.3
Current: 10.3
0
10.3
3-Year EBITDA Growth Rate 15.10
ABBV's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. ABBV: 15.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ABBV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.2 Max: 15.1
Current: 15.1
0
15.1
3-Year EPS without NRI Growth Rate 12.30
ABBV's 3-Year EPS without NRI Growth Rate is ranked higher than
59% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ABBV: 12.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ABBV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.2 Max: 12.3
Current: 12.3
0
12.3
GuruFocus has detected 4 Warning Signs with AbbVie Inc $ABBV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABBV's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ABBV Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 159,258 sh (New)
Stanley Druckenmiller 1,324,920 sh (New)
Joel Greenblatt 905,598 sh (+40.22%)
Lee Ainslie 50,540 sh (+17.07%)
Pioneer Investments 1,281,950 sh (+1.63%)
Jeff Auxier 20,672 sh (+0.49%)
Mairs and Power 269,153 sh (+0.36%)
Dodge & Cox 33,232 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,225,000 sh (unchged)
First Pacific Advisors Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 35,296 sh (-0.46%)
Murray Stahl 34,755 sh (-3.87%)
PRIMECAP Management 979,845 sh (-4.20%)
Scott Black 40,138 sh (-4.34%)
Ken Fisher 693,394 sh (-6.71%)
Larry Robbins 12,454,488 sh (-9.00%)
Tom Russo 17,106 sh (-21.24%)
Jim Simons 1,217,600 sh (-22.10%)
NWQ Managers 562,288 sh (-28.08%)
David Dreman 15,897 sh (-47.95%)
» More
Q3 2016

ABBV Guru Trades in Q3 2016

Paul Tudor Jones 8,900 sh (New)
Jim Simons 1,918,456 sh (+57.56%)
Murray Stahl 35,056 sh (+0.87%)
Stanley Druckenmiller 1,324,920 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
Tom Russo 17,106 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Jeff Auxier 20,622 sh (-0.24%)
Mairs and Power 266,453 sh (-1.00%)
Manning & Napier Advisors, Inc 157,543 sh (-1.08%)
Ken Fisher 684,042 sh (-1.35%)
Lee Ainslie 49,600 sh (-1.86%)
PRIMECAP Management 953,845 sh (-2.65%)
David Dreman 15,019 sh (-5.52%)
Scott Black 36,748 sh (-8.45%)
Pioneer Investments 1,130,994 sh (-11.78%)
Joel Greenblatt 684,356 sh (-24.43%)
Mario Gabelli 20,196 sh (-42.78%)
Larry Robbins 6,030,141 sh (-51.58%)
NWQ Managers 146,743 sh (-73.90%)
Eaton Vance Worldwide Health Sciences Fund 742,955 sh (-39.35%)
» More
Q4 2016

ABBV Guru Trades in Q4 2016

Richard Pzena 3,476 sh (New)
Steven Cohen 1,136,566 sh (New)
David Dreman 22,908 sh (+52.53%)
Larry Robbins 9,116,969 sh (+51.19%)
Joel Greenblatt 935,437 sh (+36.69%)
Scott Black 37,816 sh (+2.91%)
Lee Ainslie 50,920 sh (+2.66%)
Manning & Napier Advisors, Inc 160,726 sh (+2.02%)
Ken Fisher 696,569 sh (+1.83%)
Jeff Auxier 20,825 sh (+0.98%)
Robert Bruce 232,915 sh (unchged)
Tom Russo 17,106 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
NWQ Managers Sold Out
Mario Gabelli 20,076 sh (-0.59%)
Mairs and Power 264,365 sh (-0.78%)
Murray Stahl 33,854 sh (-3.43%)
PRIMECAP Management 901,845 sh (-5.45%)
Stanley Druckenmiller 1,221,723 sh (-7.79%)
Paul Tudor Jones 4,900 sh (-44.94%)
Jim Simons 350,800 sh (-81.71%)
Pioneer Investments 112,829 sh (-90.02%)
Eaton Vance Worldwide Health Sciences Fund 690,536 sh (-7.06%)
» More
Q1 2017

ABBV Guru Trades in Q1 2017

Leucadia National 8,008 sh (New)
Jeremy Grantham 5,500 sh (New)
NWQ Managers 4,234 sh (New)
Caxton Associates 7,100 sh (New)
Jim Simons 2,087,956 sh (+495.20%)
Paul Tudor Jones 12,162 sh (+148.20%)
Richard Pzena 4,170 sh (+19.97%)
Jeff Auxier 22,825 sh (+9.60%)
Scott Black 40,867 sh (+8.07%)
Manning & Napier Advisors, Inc 168,153 sh (+4.62%)
Dodge & Cox 33,232 sh (unchged)
Jana Partners 100,000 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Pioneer Investments Sold Out
Stanley Druckenmiller Sold Out
Murray Stahl 33,453 sh (-1.18%)
Ken Fisher 682,915 sh (-1.96%)
David Dreman 22,356 sh (-2.41%)
Mairs and Power 256,342 sh (-3.03%)
Mario Gabelli 19,376 sh (-3.49%)
Tom Russo 16,200 sh (-5.30%)
PRIMECAP Management 826,345 sh (-8.37%)
Lee Ainslie 44,400 sh (-12.80%)
Steven Cohen 940,300 sh (-17.27%)
Larry Robbins 7,301,967 sh (-19.91%)
Joel Greenblatt 618,480 sh (-33.88%)
Eaton Vance Worldwide Health Sciences Fund 187,548 sh (-72.84%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 5122
Compare:OTCPK:GLAXF, OTCPK:BAYRY, NYSE:BMY, NYSE:LLY, NYSE:AZN, NYSE:SNY, NYSE:MRK, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, NYSE:NVS, OTCPK:DSNKY, NYSE:PFE, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:GWPRF, NAS:HCM » details
Traded in other countries:ABBV34.Brazil, ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
Headquarter Location:USA
AbbVie Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the firm's current profits. The company was spun off from Abbott in early 2013.

Top Ranked Articles about AbbVie Inc

AbbVie's Humira Loses Patent in Coherus’ Petitions Why this lost patent will not hit Humira's sales
It seems that the decision of the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board to rule “in favor of Coherus’ petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135 (the 135 Patent)” as reported by Coherus Biosciences (NASDAQ:CHRS) through its Web site, is not weighing so much on AbbVie Inc. (NYSE:ABBV) whose shares have – in contrast – resumed their uptrending and are $65.40 each, up 3 cents or plus 6% from the previous trading day. Read more...
AbbVie Reports Humira Sales Growth in 1st Quarter The company beat earnings, revenue expectations
AbbVie Inc. (NYSE:ABBV) released its first-quarter 2017 financial figures on April 25. Read more...
AbbVie's Veliparib Missed Primary Endpoints of 2 Clinical Trials Investors should know that experiments were evaluated through an ITT analysis
AbbVie Inc. (NYSE:ABBV) informed the markets through PR Newswire April 19 that its PARP inhibitor, Veliparib, assessed with chemotherapy, failed to achieve two Phase 3 clinical trials' primary endpoints. Read more...
FDA Grants AbbVie Review for Imbruvica Once the application has been approved, it will be the 1st drug used in US to treat patients who are suffering from cGVHD
AbbVie (NYSE:ABBV) announced April 4 that its supplemental New Drug Application, with which the Lake Bluff, Illinois-based worldwide pharmaceutical company is looking for approval of Imbruvica (ibrutinib) for the treatment of patients affected with chronic graft-versus-host-disease (GVHD), has been granted a review by the Food and Drug Administration (FDA). Read more...
Amgen's Humira Biosimilar Approved in Europe The treatment has already been approved in the US
Amgen Inc. (NASDAQ:AMGN) announced in a news release published on its website that Amgevita, the company’s biosimilar to AbbVie Inc.’s (NYSE:ABBV) Humira (adalimumab), has been approved by the European Commission. Read more...
Galapagos Begins Cystis Fibrosis Treatment Study The study will test the treatment's safety, tolerability and pharmacokinetics
Galapagos NV (NASDAQ:GLPG), the Belgian clinical stage biotechnology company that collaborated with AbbVie Inc. (NYSE:ABBV) on a treatment for cystic fibrosis, announced March 22 the phase 1 study to assess GLPG3067’s safety, tolerability and pharmacokinetics began. Read more...
AbbVie's Hepatitis C Treatment Under Priority Review in Japan Treatment is supported by multiple studies
AbbVie Inc. (NYSE:ABBV) announced March 14 through the PRNewswire the Japanese Ministry of Health, Labor and Welfare has validated its new drug application for “its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P).” Read more...
Billionaire Investor Is Concentrating on Small-Caps and Pharma Druckenmiller is searching for value in unloved sectors of the market
Stanley Druckenmiller (Trades, Portfolio) is one of the world’s most famous hedge fund managers. His moves are scrutinized by the market for any signs of overly bullish or bearish activity thanks to his history and past performance. Read more...
Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study The study compared Xeljanz to Humira
The top-line results from the Oral Strategy trial of Xeljanz were announced Feb. 16 by Pfizer Inc. (NYSE:PFE) through the Business Wire. Read more...
AbbVie Declares Quarterly Dividend Analysts forecast increases in 2017 EPS and sales
AbbVie Inc. (NYSE:ABBV) annouced a quarterly dividend of 64 cents per share on Feb. 16. Read more...

Ratios

vs
industry
vs
history
PE Ratio 17.11
ABBV's PE Ratio is ranked higher than
75% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. ABBV: 17.11 )
Ranked among companies with meaningful PE Ratio only.
ABBV' s PE Ratio Range Over the Past 10 Years
Min: 9.85  Med: 18.49 Max: 63.37
Current: 17.11
9.85
63.37
Forward PE Ratio 12.00
ABBV's Forward PE Ratio is ranked higher than
80% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. ABBV: 12.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.11
ABBV's PE Ratio without NRI is ranked higher than
76% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. ABBV: 17.11 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABBV' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.85  Med: 18.49 Max: 63.37
Current: 17.11
9.85
63.37
Price-to-Owner-Earnings 20.02
ABBV's Price-to-Owner-Earnings is ranked higher than
68% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. ABBV: 20.02 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABBV' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.74  Med: 18.94 Max: 61.16
Current: 20.02
13.74
61.16
PB Ratio 21.07
ABBV's PB Ratio is ranked lower than
96% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. ABBV: 21.07 )
Ranked among companies with meaningful PB Ratio only.
ABBV' s PB Ratio Range Over the Past 10 Years
Min: 14.08  Med: 20.33 Max: 76.98
Current: 21.07
14.08
76.98
PS Ratio 4.09
ABBV's PS Ratio is ranked lower than
61% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ABBV: 4.09 )
Ranked among companies with meaningful PS Ratio only.
ABBV' s PS Ratio Range Over the Past 10 Years
Min: 2.83  Med: 4.15 Max: 5.68
Current: 4.09
2.83
5.68
Price-to-Free-Cash-Flow 16.34
ABBV's Price-to-Free-Cash-Flow is ranked higher than
65% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. ABBV: 16.34 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABBV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.66  Med: 14.9 Max: 38.16
Current: 16.34
8.66
38.16
Price-to-Operating-Cash-Flow 15.29
ABBV's Price-to-Operating-Cash-Flow is ranked higher than
59% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. ABBV: 15.29 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABBV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.2  Med: 13.85 Max: 31.59
Current: 15.29
8.2
31.59
EV-to-EBIT 14.61
ABBV's EV-to-EBIT is ranked higher than
70% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. ABBV: 14.61 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 15.4 Max: 42.5
Current: 14.61
10.2
42.5
EV-to-EBITDA 12.82
ABBV's EV-to-EBITDA is ranked higher than
63% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. ABBV: 12.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.6  Med: 13.6 Max: 34.1
Current: 12.82
8.6
34.1
PEG Ratio 1.80
ABBV's PEG Ratio is ranked higher than
51% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.90 vs. ABBV: 1.80 )
Ranked among companies with meaningful PEG Ratio only.
ABBV' s PEG Ratio Range Over the Past 10 Years
Min: 1.8  Med: 2.24 Max: 2.75
Current: 1.8
1.8
2.75
Current Ratio 1.76
ABBV's Current Ratio is ranked lower than
69% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. ABBV: 1.76 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 1.8 Max: 2.82
Current: 1.76
1.22
2.82
Quick Ratio 1.60
ABBV's Quick Ratio is ranked lower than
61% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. ABBV: 1.60 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.62 Max: 2.65
Current: 1.6
1.06
2.65
Days Inventory 96.60
ABBV's Days Inventory is ranked higher than
56% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. ABBV: 96.60 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s Days Inventory Range Over the Past 10 Years
Min: 35.55  Med: 89.28 Max: 115.3
Current: 96.6
35.55
115.3
Days Sales Outstanding 65.11
ABBV's Days Sales Outstanding is ranked higher than
56% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. ABBV: 65.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.11  Med: 78.73 Max: 93.3
Current: 65.11
65.11
93.3
Days Payable 84.47
ABBV's Days Payable is ranked higher than
63% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. ABBV: 84.47 )
Ranked among companies with meaningful Days Payable only.
ABBV' s Days Payable Range Over the Past 10 Years
Min: 30.33  Med: 115.54 Max: 175.86
Current: 84.47
30.33
175.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.66
ABBV's Dividend Yield % is ranked higher than
88% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. ABBV: 3.66 )
Ranked among companies with meaningful Dividend Yield % only.
ABBV' s Dividend Yield % Range Over the Past 10 Years
Min: 0.85  Med: 3.07 Max: 3.96
Current: 3.66
0.85
3.96
Dividend Payout Ratio 0.61
ABBV's Dividend Payout Ratio is ranked higher than
56% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. ABBV: 0.61 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABBV' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.61  Med: 0.64 Max: 1.51
Current: 0.61
0.61
1.51
3-Year Dividend Growth Rate 12.50
ABBV's 3-Year Dividend Growth Rate is ranked higher than
60% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. ABBV: 12.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABBV' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12.5
Current: 12.5
0
12.5
Forward Dividend Yield % 3.88
ABBV's Forward Dividend Yield % is ranked higher than
90% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. ABBV: 3.88 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.66
ABBV's 5-Year Yield-on-Cost % is ranked higher than
72% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. ABBV: 3.66 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABBV' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.85  Med: 3.07 Max: 3.96
Current: 3.66
0.85
3.96
3-Year Average Share Buyback Ratio -0.80
ABBV's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. ABBV: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABBV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.3 Max: 0
Current: -0.8
-0.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.64
ABBV's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
65% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. ABBV: 1.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABBV' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.62  Med: 1.72 Max: 1.86
Current: 1.64
1.62
1.86
Price-to-Median-PS-Value 0.98
ABBV's Price-to-Median-PS-Value is ranked higher than
64% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. ABBV: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABBV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.71  Med: 0.99 Max: 1.27
Current: 0.98
0.71
1.27
Price-to-Peter-Lynch-Fair-Value 2.20
ABBV's Price-to-Peter-Lynch-Fair-Value is ranked lower than
79% of the 174 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. ABBV: 2.20 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABBV' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.11  Med: 2.26 Max: 2.7
Current: 2.2
2.11
2.7
Earnings Yield (Greenblatt) % 6.84
ABBV's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. ABBV: 6.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABBV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.4  Med: 6.5 Max: 9.8
Current: 6.84
2.4
9.8
Forward Rate of Return (Yacktman) % 13.20
ABBV's Forward Rate of Return (Yacktman) % is ranked higher than
53% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. ABBV: 13.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABBV' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.8  Med: 13.2 Max: 14.4
Current: 13.2
11.8
14.4

More Statistics

Revenue (TTM) (Mil) $26,218
EPS (TTM) $ 3.86
Beta1.45
Short Percentage of Float2.14%
52-Week Range $55.06 - 68.12
Shares Outstanding (Mil)1,591.54

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 27,885 30,137 31,849
EPS ($) 5.50 6.43 7.19
EPS without NRI ($) 5.50 6.43 7.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.93%
Dividends per Share ($) 2.58 2.74 2.85
» More Articles for ABBV

Headlines

Articles On GuruFocus.com
AbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference May 24 2017 
What Drug Approval Means for Neurocrine Biosciences May 19 2017 
AbbVie's Humira Loses Patent in Coherus’ Petitions May 18 2017 
IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical E May 14 2017 
AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1- May 09 2017 
AbbVie to Present at the UBS Global Healthcare Conference May 05 2017 
AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking St May 04 2017 
AbbVie Reports Humira Sales Growth in 1st Quarter Apr 28 2017 
AbbVie’s Humira Revenue Up 15% Despite Patent Cliff Fears Apr 28 2017 
Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthr Apr 25 2017 

More From Other Websites
Blog Coverage: Pfizer Cautions Shareholders Against Accepting TRC Capital Corporation's Mini-Tender... May 26 2017
Major Pharma Short Interest Surges May 25 2017
Biogen's Fampyra Conditional Approval Converted to Standard May 25 2017
Neupogen and Enbrel Could See Falling Revenues in 2017 May 24 2017
AbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference May 24 2017
AbbVie Expects Rivals To Chip Away At Its Biggest Drug Franchise May 23 2017
Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis May 23 2017
The 3 Best Dividend Stocks in Arthritis Medication May 22 2017
[$$] AmerisourceBergen and AbbVie Top Barron's 500 May 20 2017
The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco May 19 2017
AbbVie to Present at the Jefferies 2017 Global Healthcare Conference May 19 2017
For millions of Chinese with rare diseases, some relief in sight May 18 2017
AbbVie's Humira Loses Patent in Coherus' Petitions May 18 2017
Top 4 Marijuana Stocks to Watch for 2017 May 18 2017
New Stock Research Reports for Boeing, AbbVie and UnitedHealth May 18 2017
[$$] AbbVie: It's the Pipeline, Not the Coherus Ruling May 18 2017
AbbVie Down on Humira Patent Loss: Is More Damage in Store? May 18 2017
AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : May 18, 2017 May 18 2017
AbbVie Loses Key Humira Patent In Battle With Small-Cap Biotech May 17 2017
AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd... May 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)